Galectin Therapeutics (GALT) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (NASDAQ: GALT) today and set a price target of $12. The company’s shares opened today at $3.73.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.4% and a 39.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Avenue Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galectin Therapeutics with a $12 average price target.

See today’s analyst top recommended stocks >>

Based on Galectin Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.84 million. In comparison, last year the company had a GAAP net loss of $4.51 million.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2018, Jack Callicutt, the CFO of GALT sold 226,000 shares for a total of $1,945,802.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts